Resilient T-cell responses in patients with advanced cancers

Joanina K. Gicobi, Emilia R. Dellacecca, Haidong Dong

Research output: Contribution to journalReview articlepeer-review


Although cancer burden in patients with advanced disease results in many failed prior therapies, some patients still achieve durable responses to immunotherapy implying that remnant and resilient cytotoxic T cells are present in these responders. Since patients with more resilient T cells are likely to benefit from immunotherapy, it will be important to determine how resilient T cells in patients can be identified and to define the mechanisms by which tumor-reactive resilient T cells can be generated. In this review, we summarized recent advances in research on resilient T cells in patients with advanced cancers and proposed future research directions. From there, we expect to leverage this knowledge to generate or expand the resilient T cells in patients who do not respond to initial immunotherapy and convert them into responders.

Original languageEnglish (US)
JournalInternational journal of hematology
StateAccepted/In press - 2022


  • Cancer immunotherapy
  • CX3CR1
  • Cytotoxic T cells
  • NKG7
  • T cell resilience

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Resilient T-cell responses in patients with advanced cancers'. Together they form a unique fingerprint.

Cite this